Targeting RAS and PI3K in lung cancer
J Downward - Nature medicine, 2008 - nature.com
Nature medicine, 2008•nature.com
The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major
tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to
shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung
tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages
1351–1356).
tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to
shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung
tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages
1351–1356).
The phosphoinositide 3-kinase (PI3K) and RAS oncoproteins are activated in many major tumor types and control linked signaling pathways. An inhibitor of PI3K is now shown to shrink tumors in transgenic mouse cancer models. The drug also blocks RAS-induced lung tumors when combined with an inhibitor of mitogen-activated protein kinase kinase (pages 1351–1356).
nature.com